{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:06Z","timestamp":1792592346649,"version":"4.5.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Drug-induced autoimmune-like hepatitis (DI-ALH) is a potentially life-threatening condition that can lead to acute liver failure and necessitate liver transplantation. While the association between certain drugs and DI-ALH has been documented, a comprehensive analysis of drug-related signals in a large, real-world pharmacovigilance database is lacking. This study aimed to systematically identify drugs linked to DI-ALH by analyzing adverse event reports from the U.S. Food and Drug Administration\u2019s (FDA) Adverse Event Reporting System (FAERS) database.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We searched the FAERS database for the term \"autoimmune hepatitis\" and extracted DI-ALH reports from the first quarter of 2004 to the first quarter of 2024. Positive signal drugs were identified using Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM). To confirm a significant drug-adverse event association, each method had to meet predefined thresholds: for PRR and ROR, values were considered significant if the lower 95% confidence interval (CI) was greater than 1 and at least three reports were identified; for BCPNN, an Information Component (IC025) greater than 0 indicated a signal; for EBGM, a value greater than 2 for the lower 95% confidence interval (EBGM05) was used to denote a positive signal.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 5,723 DI-ALH reports were extracted from the FAERS database. Disproportionality analysis identified 50 drugs with strong associations to DI-ALH, with biologics, statins, antibiotics, and antiviral drugs representing the most common categories. Among these, nitrofurantoin (ROR 94.79, CI 78.53\u2013114.41), minocycline (ROR 77.82, CI 65.09\u201393.05), and nivolumab (ROR 47.12, CI 15.06\u2013147.39) exhibited the strongest signals. Additionally, several previously unreported drugs, including mesalazine, aldesleukin, onasemnogene abeparvovec-xioi, and nefazodone, were identified as having strong associations with DI-ALH. These findings were consistent across all four signal detection methods, further validating the robustness of the associations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study provides a comprehensive assessment of drugs associated with DI-ALH through a rigorous analysis of the FAERS database using multiple signal detection methods. By identifying both well-known and previously underreported drugs, this study contributes to a more complete understanding of drug-induced liver injury. The findings have important implications for pharmacovigilance strategies and clinical risk assessment. However, limitations inherent in the FAERS database, such as underreporting and the potential for reporting bias, should be considered. Further clinical validation is warranted to confirm these associations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0317680","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:42:27Z","timestamp":1738867347000},"page":"e0317680","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database"],"prefix":"10.1371","volume":"20","author":[{"given":"Wangyu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9695-4860","authenticated-orcid":true,"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"6","key":"pone.0317680.ref001","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"pone.0317680.ref002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management","volume":"97","author":"HK Bj\u00f6rnsson","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"8","key":"pone.0317680.ref003","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/10937404.2023.2261848","article-title":"Drug induced liver injury\u2014a 2023 update","volume":"26","author":"R Allison","year":"2023","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"10","key":"pone.0317680.ref004","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"M Garcia-Cortes","year":"2020","journal-title":"Arch Toxicol"},{"issue":"1","key":"pone.0317680.ref005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"RJ Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"pone.0317680.ref006","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"ES Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"issue":"9","key":"pone.0317680.ref007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091954","article-title":"\"Autoimmune(-Like)\" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis","volume":"18","author":"M Sebode","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3","key":"pone.0317680.ref008","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report","volume":"79","author":"RJ Andrade","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0317680.ref009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ueg2.12499","article-title":"Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study","volume":"12","author":"Y Chung","year":"2024","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"pone.0317680.ref010","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jhep.2024.01.023","article-title":"Distinction of autoimmune hepatitis from drug-induced autoimmune like hepatitis: The answer lies at the interface","volume":"81","author":"A Alkashash","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0317680.ref011","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"C Sgro","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"pone.0317680.ref012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/hepr.12530","article-title":"Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis","volume":"46","author":"UB Kuzu","year":"2016","journal-title":"Hepatol Res"},{"issue":"12","key":"pone.0317680.ref013","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.dld.2014.08.040","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study","volume":"46","author":"A Licata","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"10","key":"pone.0317680.ref014","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-Induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse After Cessation of Steroids","volume":"15","author":"ES Bj\u00f6rnsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0317680.ref015","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jhep.2010.12.041","article-title":"Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis","volume":"55","author":"MI Lucena","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0317680.ref016","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000511635","article-title":"Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury","volume":"39","author":"S Weber","year":"2021","journal-title":"Dig Dis"},{"issue":"3","key":"pone.0317680.ref017","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"A Suzuki","year":"2011","journal-title":"Hepatology"},{"issue":"8","key":"pone.0317680.ref018","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-011-1787-7","article-title":"Drug-induced autoimmune-like hepatitis: a diagnostic challenge","volume":"56","author":"A Castiella","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"6","key":"pone.0317680.ref019","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"E Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"pone.0317680.ref020","doi-asserted-by":"crossref","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"M Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"pone.0317680.ref021","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration","volume":"23","author":"HJ Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"12","key":"pone.0317680.ref022","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.4049\/jimmunol.1201286","article-title":"IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells","volume":"189","author":"A-K Heninger","year":"2012","journal-title":"J Immunol"},{"issue":"4","key":"pone.0317680.ref023","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis","volume":"56","author":"AJ Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"4","key":"pone.0317680.ref024","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10620-009-0805-5","article-title":"Meloxicam as a cause of drug-induced autoimmune hepatitis","volume":"55","author":"P Mart\u00ednez-Odriozola","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"1","key":"pone.0317680.ref025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cld.2019.09.007","article-title":"Drug-Induced Liver Injury from Statins","volume":"24","author":"L Meurer","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"3","key":"pone.0317680.ref026","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1111\/hepr.12532","article-title":"Natural history and outcomes in drug-induced autoimmune hepatitis","volume":"46","author":"TT Yeong","year":"2016","journal-title":"Hepatol Res"},{"key":"pone.0317680.ref027","doi-asserted-by":"crossref","DOI":"10.2147\/CEG.S101440","article-title":"Autoimmune hepatitis: current challenges and future prospects","volume":"10","author":"Y Aizawa","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"issue":"3","key":"pone.0317680.ref028","doi-asserted-by":"crossref","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","article-title":"Statin-induced Liver Injury Patterns: A Clinical Review","volume":"10","author":"LD Averbukh","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"pone.0317680.ref029","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/17425255.2016.1211110","article-title":"Autoimmune-like drug-induced liver injury: a review and update for the clinician","volume":"12","author":"JG Stine","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"pone.0317680.ref030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"ST Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"pone.0317680.ref031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s10020-020-00256-1","article-title":"Escape from X chromosome inactivation and female bias of autoimmune diseases","volume":"26","author":"MJ Mousavi","year":"2020","journal-title":"Mol Med"},{"key":"pone.0317680.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2019.11.004","article-title":"Pregnancy and autoimmune diseases","volume":"64","author":"EC Somers","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2\u20133","key":"pone.0317680.ref033","doi-asserted-by":"crossref","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"OL Quintero","year":"2012","journal-title":"J Autoimmun"},{"issue":"9","key":"pone.0317680.ref034","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S2468-1253(20)30006-6","article-title":"Drug-induced liver injury in older people","volume":"5","author":"MI Lucena","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"pone.0317680.ref035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1515\/aiht-2017-68-2994","article-title":"Hepatotoxicity associated with statins","volume":"68","author":"B Karahalil","year":"2017","journal-title":"Arh Hig Rada Toksikol"},{"key":"pone.0317680.ref036","first-page":"15","volume-title":"Mitochondrial Diseases","author":"NBB Estela","year":"2017"},{"issue":"9","key":"pone.0317680.ref037","first-page":"399","article-title":"Statins and autoimmunity","volume":"145","author":"M Alvarado C\u00e1rdenas","year":"2015","journal-title":"Med Clin (Barc)"},{"issue":"Pt 5","key":"pone.0317680.ref038","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1258\/0004563054890105","article-title":"Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe","volume":"42","author":"C. van Heyningen","year":"2005","journal-title":"Ann Clin Biochem"},{"issue":"11","key":"pone.0317680.ref039","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"pone.0317680.ref040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"M Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"pone.0317680.ref041","doi-asserted-by":"crossref","first-page":"44","DOI":"10.11604\/pamj.2023.44.44.38646","article-title":"Ustekinumab-induced autoimmune hepatitis: a case report","volume":"44","author":"AS Samah","year":"2023","journal-title":"Pan Afr Med J"},{"issue":"5","key":"pone.0317680.ref042","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-239944","article-title":"Infliximab-induced autoimmune hepatitis","volume":"14","author":"A Jenkins","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"13\u201314","key":"pone.0317680.ref043","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.drudis.2007.05.002","article-title":"Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy","volume":"12","author":"J Bayry","year":"2007","journal-title":"Drug Discov Today"},{"issue":"1","key":"pone.0317680.ref044","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2013.09.016","article-title":"Drug-induced liver injury","volume":"89","author":"MD Leise","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"pone.0317680.ref045","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","article-title":"A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab","volume":"32","author":"S-Y Kawashiri","year":"2012","journal-title":"Rheumatol Int"},{"issue":"8","key":"pone.0317680.ref046","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"ES Bj\u00f6rnsson","year":"2022","journal-title":"Hepatol Commun"},{"issue":"24","key":"pone.0317680.ref047","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","article-title":"Drug-induced autoimmune hepatitis: A minireview","volume":"28","author":"CK Tan","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"3","key":"pone.0317680.ref048","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ncpgasthep1055","article-title":"A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis","volume":"5","author":"C Abraham","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"4 Pt 1","key":"pone.0317680.ref049","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/0016-5085(92)90786-X","article-title":"Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C","volume":"102","author":"M Shindo","year":"1992","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0317680.ref050","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/1319-3767.84494","article-title":"Concurrent autoimmune hepatitis and grave\u2019s disease in hepatitis C during pegylated interferon \u03b1-2a and ribavirin therapy","volume":"17","author":"GV Trikudanathan","year":"2011","journal-title":"Saudi J Gastroenterol"},{"issue":"4","key":"pone.0317680.ref051","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14309\/crj.2015.74","article-title":"Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon \u03b1-2a and Ribavirin for Chronic Hepatitis C","volume":"2","author":"C Rathi","year":"2015","journal-title":"ACG Case Rep J"},{"issue":"18","key":"pone.0317680.ref052","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2169\/internalmedicine.0613-17","article-title":"Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection","volume":"57","author":"K Matsumoto","year":"2018","journal-title":"Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:42:43Z","timestamp":1738867363000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317680"}},"subtitle":[],"editor":[{"given":"Cheung","family":"Kenneth Chat Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317680","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}